<DOC>
	<DOCNO>NCT01268150</DOCNO>
	<brief_summary>The purpose study assess efficacy safety single-agent eribulin mesylate first-line treatment subject locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>A Study Single-Agent Eribulin Mesylate First-Line Therapy Locally Recurrent Metastatic Human Epidermal Growth Factor Receptor Two ( HER2 ) Negative Breast Cancer</brief_title>
	<detailed_description>This multicenter , single-arm , Phase 2 trial ass efficacy safety single-agent eribulin mesylate first-line treatment subject locally recurrent metastatic human epidermal growth factor receptor ( HER2 ) -negative breast cancer . A total 52 adult female subject enrol treated eribulin mesylate ( 1.4 mg/m2 intravenous [ i.v . ] infusion 2 5 minute Days 1 8 3-week cycle ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Key Inclusion Criteria Females age 18 year old time inform consent Have histologically cytologically proven adenocarcinoma breast Subjects locally recurrent metastatic disease least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria v 1.1 Human epidermal growth factor receptor ( HER2 ) negative disease determine fluorescence situ hybridization ( FISH ) 0 1+ immunohistochemical ( IHC ) staining . Life expectancy great 24 week Eastern Cooperative Oncology Group ( ECOG ) Performance Score ( PS ) 0 , 1 2 At least 12 month since prior neoadjuvant adjuvant chemotherapy At least 2 week since prior radiotherapy endocrine therapy , complete recovery effect intervention Adequate renal function Adequate bone marrow function Adequate liver function Key Exclusion Criteria Subjects meet follow criterion exclude participation study : Prior chemotherapy , biologic therapy , investigational therapy locally recurrent metastatic breast cancer Subjects prior malignancy carcinoma situ cervix nonmelanoma skin cancer Prior exposure great 360 mg/m2 doxorubicin liposomal doxorubicin , great 120 mg/m2 mitoxantrone , great 90 mg/m2 idarubicin , great than720 mg/m2 epirubicin Inflammatory breast cancer Clinically significant cardiovascular impairment Subjects know CNS disease eligible , except treat brain metastasis . Pulmonary lymphangitic involvement result pulmonary dysfunction require use oxygen Currently pregnant breastfeed . Subjects preexist Grade 3 4 neuropathy . Any peripheral neuropathy must recover Grade 2 enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>